Please login to the form below

Not currently logged in
Email:
Password:

dimethyl fumarate

This page shows the latest dimethyl fumarate news and features for those working in and with pharma, biotech and healthcare.

Biogen raises full year guidance after beating Q2 expectations

Biogen raises full year guidance after beating Q2 expectations

Total revenues for the second quarter climbed 1.8% to $3.68bn, with sales boosted by Biogen’s multiple sclerosis therapy Tecfidera (dimethyl fumarate) which generated sales of $1.18bn – beating

Latest news

  • Biogen triumphs over Mylan’s Tecfidera patent challenge Biogen triumphs over Mylan’s Tecfidera patent challenge

    The challenge from Mylan focused on Biogen’s ‘514 patent on Tecfidera (dimethyl fumarate) , which is due to expire in 2028. ... Biogen does, however, have its own next-generation MS treatment – Vumerity (diroximel fumarate) – which was recently

  • Biogen under fire over $88,000 Vumerity annual price Biogen under fire over $88,000 Vumerity annual price

    Biogen and partner Alkermes scored FDA approval for Vumerity (diroximel fumarate) on the 30 October for the treatment of relapsing forms of MS. ... In comparison, Biogen’s older oral MS drug Tecfidera (dimethyl fumarate) entered the market with a price

  • Merck takes evobrutinib for MS into phase 3, on mixed data Merck takes evobrutinib for MS into phase 3, on mixed data

    If successful, Merck will have a chance to bring forward a new-mechanism therapy for relapsing MS that will compete with blockbuster oral drugs such as Biogen’s Tecfidera (dimethyl fumarate), ... It will also have to contend with newer drugs like

  • Tecfidera successor’s side-effect profile boosts Biogen Tecfidera successor’s side-effect profile boosts Biogen

    Now Biogen has unveiled promising results from its head-to-head study of Tecfidera (dimethyl fumarate) versus its tweaked follow-on molecule, diroximel fumarate in the five-week EVOLVE-MS-2 ... trial. The trial showed that diroximel fumarate – to be

  • Biogen trumpets safety data for Tecfidera follow-up Biogen trumpets safety data for Tecfidera follow-up

    to hear the outcome of a patent challenge on Tecfidera (dimethyl fumarate) in the US from Mylan. ... enhancing lesions in the brain reduced by 64% with diroximel fumarate compared to baseline.

More from news
Approximately 11 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    Biogen. Patent settlement. Tecfidera (dimethyl fumarate). 1, 250. Merrimack Pharamceuti-cals. Ipsen.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Executive vice president of Biogen leaves Executive vice president of Biogen leaves

    Kingsley joined Biogen in 2010 as senior VP and during his tenure Biogen introduced five new therapies including successfully launching Tecfidera (dimethyl fumarate) – the most prescribed oral treatment for multiple sclerosis.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals
Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....

Infographics